Enter assignee name

Trademarks = 1

Forward Citations = 0

Loading Chart...

8 inventors (with patents filed for the assignee):

David Stover (9 out of 11 patents)

Bruce Allan Hay (8 out of 24 patents)

Tahmineh Safaie (8 out of 8 patents)

4. Dhruba Bharali (8 out of 8 patents)

5. Alex Vasuthasawat (1 out of 4 patents)

6. Kham Trinh (1 out of 3 patents)

7. George Ayoub (1 out of 3 patents)

8. Sherie Morrison (1 out of 1 patent)

9 patents: Sort by Forward Citations

1. 12311010 - Formulated and/or co-formulated liposome compositions containing toll-like receptor('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2025-05-27),

2. 12286403 - Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof (2025-04-29),

3. 12162958 - Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof (2024-12-10),

4. 12059470 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof (2024-08-13),

5. 11896646 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2024-02-13),

6. 11833209 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof (2023-12-05),

7. 11801304 - Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof (2023-10-31),

8. 11744874 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2023-09-05),

9. 11679141 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof (2023-06-20),

Nammi Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Our innovative research and development approach aims to target specific pathways within cancer cells to improve patient outcomes. Through collaboration with leading academic institutions and industry partners, we are dedicated to advancing the field of oncology and bringing new treatment options to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

9 Patents

#208 in Los Angeles, CA

#7,510 in California

#31,660 in US

Los Angeles, CA, United States of America

Nammi Therapeutics, Inc.